| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910595001003321 |
|
|
Autore |
Bowler Chris |
|
|
Titolo |
La biodiversité et les écosystèmes à travers le temps et l’espace : Leçon inaugurale prononcée le jeudi 4 février 2021 / / Chris Bowler |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Paris, : Collège de France, 2022 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (80 p.) |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
|
|
Soggetti |
|
Environmental Studies |
Multidisciplinary |
environnement |
biodiversité |
changement climatique |
ressources naturelles |
océan |
biologie |
écosystèmes |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Sommario/riassunto |
|
Après 4,5 milliards d’années d’évolution, notre planète s’épuise du fait de l’exploitation intensive des énergies fossiles et de l’eau, de la surconsommation d’engrais agricoles et de la déforestation. Elle pourrait vivre la plus importante des extinctions massives. Observer les organismes avec lesquels nous cohabitons permet de mieux comprendre les fonctions de chacun et de percevoir l’ampleur des phénomènes en cours, qui engagent dès à présent l’avenir de l’humanité : perte de la biodiversité, dégradation des écosystèmes, changement climatique, épidémies. Face à ce constat alarmant, les scientifiques ont un rôle déterminant à jouer : produire des modèles et formuler des prédictions pour susciter des actions politiques concrètes. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910676604103321 |
|
|
Titolo |
Bioinorganic medicinal chemistry / / edited by Enzo Alessio |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Weinheim, Germany, : bWiley-VCH, c2011 |
|
|
|
|
|
|
|
ISBN |
|
9786613370488 |
9783527633128 |
352763312X |
9781283370486 |
1283370484 |
9783527633111 |
3527633111 |
9783527633104 |
3527633103 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (442 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Pharmaceutical chemistry |
Bioinorganic chemistry |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Bioinorganic Medicinal Chemistry; Contents; List of Contributors; 1: Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future: Nicola J. Farrer and Peter J. Sadler; 1.1: Introduction; 1.1.1: Metals in the Body: Essential Elements and Diseases of Metabolism; 1.1.2: Metals as Therapeutic Agents; 1.2: Antimicrobial Agents; 1.3: Antiviral Agents; 1.4: Systemic and Metabolic Diseases Including Inflammation; 1.4.1: Diabetes and Obesity; 1.4.2: Metal Homeostasis and Related Diseases; 1.5: Metal Chelating Agents; 1.6: Antiarthritic Drugs and Inflammation |
1.7: Bipolar Disorder1.8: Anticancer Agents; 1.8.1: PtII Cytotoxic Agents; 1.8.2: PtIV Prodrugs; 1.8.3: Photoactivatable PtIV Complexes; 1.8.4: Ruthenium; 1.8.4.1: Interaction with Plasma Proteins; 1.8.4.2: Ruthenium Arenes; 1.8.5: Osmium; 1.8.6: Titanium; 1.8.7: Gold; 1.8.8: Tin; 1.8.9: Gallium; 1.8.10: Arsenic; 1.8.11: Copper; 1.8.12: Zinc; |
|
|
|
|
|
|
|
|
|
|
|
1.8.13: Bismuth; 1.8.14: Molybdenum; 1.8.15: Photosensitizers: Porphyrins; 1.9: Small Molecule Delivery and Control; 1.9.1: Nitric Oxide (NO); 1.9.2: Carbon Monoxide (CO); 1.10: Diagnostic Agents; 1.11: Veterinary Medicinal Inorganic Chemistry |
1.12: Conclusions and Vision2: Targeting Strategies for Metal-Based Therapeutics: Julia F. Norman and Trevor W. Hambley; 2.1: Introduction; 2.2: Physiological Targeting; 2.2.1: Antitumor Drugs Targeting Tumor Hypoxia; 2.2.2: Antitumor Drugs Targeting Vascular Structure; 2.2.3: Antitumor Drugs Targeting Tumor pH; 2.2.4: Light Activated Prodrugs; 2.3: Molecular Targeting; 2.3.1: Protein and Peptide Targeting; 2.3.1.1: Protein Receptor Binding; 2.3.2: Peptide Tethering; 2.3.2.1: Directing Effects; 2.3.3: Selective Activation; 2.3.4: DNA Targeting; 2.3.4.1: Duplex DNA Sequence Selectivity |
2.3.4.2: Telomeric Targeting2.4: Immunological Targeting; 2.4.1: Antigen Targeting; 2.4.2: Antibody Tethering; 2.5: Concluding Remarks; 3: Current Status and Mechanism of Action of Platinum-Based Anticancer Drugs: Shanta Dhar and Stephen J. Lippard; 3.1: Introduction; 3.1.1: Platinum Chemotherapy and Cancer; 3.1.2: Palette of Current Platinum Chemotherapeutic Drugs; 3.1.3: Early History of Cisplatin and Approved Platinum Drugs for the Clinic; 3.2: Mechanism of Action of Cisplatin; 3.2.1: Cisplatin Accumulation; 3.2.2: Cisplatin Activation; 3.2.2.1: Binding to DNA Targets |
3.2.2.2: Binding to Non-DNA Targets3.2.3: Cellular Processing of Platinum-DNA Adducts; 3.2.3.1: Cytotoxicity Associated with High Mobility Group (HMG) Proteins; 3.2.3.2: Cytotoxicity Associated with Non-HMG Proteins; 3.3: Limitations of Current Platinum-Based Compounds: New Strategies; 3.4: Novel Concepts in the Development of Platinum Antitumor Drugs; 3.4.1: Functionalized Single-Walled Carbon Nanotubes (SWNTs) as Vehicles for Delivery of Pt(IV)-Prodrugs; 3.4.2: Targeted Nanoparticles for Delivery of Cisplatin for Prostate Cancer |
3.4.3: Gold Nanoparticles as Delivery Vehicles for Platinum Compounds |
|
|
|
|
|
|
Sommario/riassunto |
|
This book gives a comprehensive overview about medicinal inorganic chemistry. Topics like targeting strategies, mechanism of action, Pt-based antitumor drugs, radiopharmaceuticals are covered in detail and offer the reader an in-depth overview about this important topic. |
|
|
|
|
|
|
|
| |